

August 1, 2018

BSE Limited

1st Floor, P J Towers,
Dalal Street,
Mumbai-400001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai-400051

Re.: Press Release.

Dear Sir / Madam,

We enclose herewith a copy of press release dated August 1, 2018 titled "Zydus receives final approval from the USFDA for Azithromycin for Oral Suspension USP".


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus receives final approval from the USFDA for Azithromycin for Oral Suspension USP

Ahmedabad, 01 August, 2018

Zydus Cadila has received the final approval from the USFDA to market Azithromycin for Oral Suspension USP (US RLD - Zithromax), 100 mg/5 mL and 200 mg/5 mL.

This medication contains Azithromycin, a macrolide antibiotic that fights bacteria. It is used to treat different types of bacterial infections such as respiratory infections, skin infections, ear infections and sexually transmitted diseases. This medication will not work for viral infections such as common cold, flu etc. The drug will be manufactured at the group's formulations manufacturing facility at Baddi.

In line with this, the group now has 213 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
